Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens

Haematologica

Volumn 96, Issue 5, 2011, Pages 729-737

  Du, Juan ^a   Huo, Jun ^a   Shi, Jun ^b   Yuan, Zhengang ^a   Zhang, Chunyang ^a   Fu, Weijun ^a   Jiang, Hua ^a   Yi, Qing ^c   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Multiple myeloma; NF B; SNP

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; IKBALPHA GENE; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NFKB2 GENE; NUCLEAR FACTOR KAPPA B GENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRAF3 GENE; TREATMENT OUTCOME; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; BORONIC ACIDS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; I-KAPPA B PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NF-KAPPA B P52 SUBUNIT; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRAZINES; RISK ASSESSMENT; RISK FACTORS; TNF RECEPTOR-ASSOCIATED FACTOR 3; TREATMENT OUTCOME;

EID: 79955738089     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030577     Document Type: Article

References (45)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
2. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33-40.
3. Basseres DS, Baldwin AS. Nuclear factorkappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817-6830.
4. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700-2707.
5. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92(9): 1224-1229.
6. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25(51):6800-6816.
7. Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol. 2005;25(6):541-550.
8. Burstein E, Duckett CS. Dying for NFkappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003;15(6):732-737.
9. Anderson KC. Proteasome inhibitors in multiple myeloma. Semin Oncol. 2009;36(2 Suppl 1):S20-S26.
10. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl) retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factorkappaB- regulated gene products. Cancer Res. 2005;65(20):9555-9565.
11. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130.
12. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144.
13. Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV, et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science. 2001;291(5511):2162-5.
14. Tucker E, O'Donnell K, Fuchsberger M, Hilton AA, Metcalf D, Greig K, et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 super repressor. J Immunol. 2007;179(11):7514-7522.
15. Hauer J, Puschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5 mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA. 2005;102(8):2874-289.
16. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptorassociated factor 3-induced degradation. J Biol Chem. 2004;279(25):26243-26250.
17. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297-309.
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609-17.
19. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498.
20. San MJF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
21. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008; 14(6):1649-1657.
22. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van RF, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625-634.
23. Rajkumar SV, Sonneveld P. Front-line treatment in younger patients with multiple myeloma. Semin Hematol. 2009;46(2):118-126.
24. Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, et al. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet. 2002;137(1):43-48.
25. Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett. 2007;246(1-2):92-99.
26. Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen JT, et al. A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis. 2004;19(2):153-156.
27. Mozzato-Chamay N, Corbett EL, Bailey RL, Mabey DC, Raynes J, Conway DJ. Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun. 2001;2(3):153-155.
28. Abdallah A, Sato H, Grutters JC, Veeraraghavan S, Lympany PA, Ruven HJ, et al. Inhibitor kappa B-alpha (IkappaBalpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun. 2003;4(6):450-454.
29. Chapman SJ, Khor CC, Vannberg FO, Frodsham A, Walley A, Maskell NA, et al. IkappaB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med. 2007;176(2):181-187.
30. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
31. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-1123.
32. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
33. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97-8.
34. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition-ligation-combinationsubdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19(4):519-523.
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-75.
36. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978-89.
37. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73(5):1162-9.
38. De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science. 2006;312(5777):1215-7.
39. von AN, Oellerich M. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood. 2004;103(2):586-593.
40. Li SC, Tang P, Lin WC. Intronic microRNA: discovery and biological implications. DNA Cell Biol. 2007;26(4):195-207.
41. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114(5):1046-1052.
42. Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010;24(3 Suppl 2):22-9.
43. Mateos MV, Oriol A, Martinez J, Cibeira MT, Gutiérrez NC, Terol MJ, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/ prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/ prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 3.
44. Reece DE, Trieu Y, Chen C, Kukreti V, Xu W, Anglin P, et al. Sequencing Novel Agents in relapsed/refractory multiple myeloma: use of bortezomib-based therapy after lenalidomide + dexamethasone. Blood (ASH Annual Meeting Abstracts). 2009;114 (22):Abstract 1853.
45. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82(3):323-341.